FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1865367030> ?p ?o ?g. }

• W1865367030 endingPage "787" @default.
• W1865367030 startingPage "779" @default.
• W1865367030 abstract "PURPOSE The United Kingdom Central Lymphoma Group (CLG) has modified mechlorethamine, vincristine, procarbazine, and prednisone/doxorubicin, bleomycin, vinblastine, and dacarbazine (MOPP/ABVD) by substituting mechlorethamine with chlorambucil and dacarbazine with etoposide in the treatment of patients with advanced Hodgkin's disease (HD). Prednisolone is included in the bleomycin-containing combination, and the vinca alkaloids have been switched to balance the myelotoxicity of the two component regimens. PATIENTS AND METHODS The resulting ChlVPP/PABlOE regimen is as follows: on days 1 to 14, chlorambucil 6 mg/m2 orally, procarbazine 100 mg/m2 orally, and prednisolone 30 mg/m2 orally; on days 1 and 8, vinblastine 6 mg/m2 intravenously (i.v.); on day 29, doxorubicin 40 mg/m2 i.v.; on days 29 and 36, vincristine 1.4 mg/m2 (maximum, 2 mg) i.v., and bleomycin 10 mg/m2 i.v.; on days 30, 31, and 32, etoposide 200 mg/m2/d orally; on days 29 to 43, inclusive, prednisolone, 30 mg/m2 orally. The second full cycle restarts on day 50. Treatment continues to maximum response plus two full cycles, but with a minimum of three full cycles. Radiotherapy is administered, after chemotherapy, to sites of previously bulky disease. Since 1983, 216 patients with previously untreated, advanced Hodgkin's disease (HD) have entered this study. RESULTS The complete remission (CR) rate after chemotherapy was 73% (95% confidence interval [CI], 67% to 79%), and after additional radiotherapy was 85% (95% CI, 80% to 90%). The failure-free survival (FFS) rate at 5 years was 68% (95% CI, 61% to 74%), and the overall actuarial survival at 5 years was 78% (95% CI, 72% to 84%). The CR rate in patients in the poorer prognostic categories was high: 81% in patients with albumin levels less than 37 g/L, 79% in patients older than 40 years of age, 84% in stages IIIB plus i.v. disease, and 79% in patients presenting with B symptoms. As expected, nausea and vomiting were not major problems, although infection, often in the context of myelosuppression, complicated almost half the cases, and 29% of patients required admission at some stage for treatment of infection. CONCLUSION In this multicenter study, ChlVPP/PABlOE produced results comparable to those reported for MOPP/ABVD, but with less nausea and vomiting. Treatment duration was shorter than in the original MOPP/ABVD regimen, and than that used in the Cancer and Leukemia Group B (CALGB) trial. It will now be compared with PABlOE alone." @default.
• W1865367030 created "2016-06-24" @default.
• W1865367030 creator A5021680577 @default.
• W1865367030 creator A5024501263 @default.
• W1865367030 creator A5036572342 @default.
• W1865367030 creator A5037342439 @default.
• W1865367030 creator A5041465210 @default.
• W1865367030 creator A5051229176 @default.
• W1865367030 creator A5072059432 @default.
• W1865367030 creator A5078201837 @default.
• W1865367030 creator A5082102746 @default.
• W1865367030 date "1994-04-01" @default.
• W1865367030 modified "2023-09-26" @default.
• W1865367030 title "ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group." @default.
• W1865367030 doi "https://doi.org/10.1200/jco.1994.12.4.779" @default.
• W1865367030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7512132" @default.
• W1865367030 hasPublicationYear "1994" @default.
• W1865367030 type Work @default.
• W1865367030 sameAs 1865367030 @default.
• W1865367030 citedByCount "24" @default.
• W1865367030 countsByYear W18653670302014 @default.
• W1865367030 crossrefType "journal-article" @default.
• W1865367030 hasAuthorship W1865367030A5021680577 @default.
• W1865367030 hasAuthorship W1865367030A5024501263 @default.
• W1865367030 hasAuthorship W1865367030A5036572342 @default.
• W1865367030 hasAuthorship W1865367030A5037342439 @default.
• W1865367030 hasAuthorship W1865367030A5041465210 @default.
• W1865367030 hasAuthorship W1865367030A5051229176 @default.
• W1865367030 hasAuthorship W1865367030A5072059432 @default.
• W1865367030 hasAuthorship W1865367030A5078201837 @default.
• W1865367030 hasAuthorship W1865367030A5082102746 @default.
• W1865367030 hasConcept C126322002 @default.
• W1865367030 hasConcept C141071460 @default.
• W1865367030 hasConcept C2776232574 @default.
• W1865367030 hasConcept C2776305933 @default.
• W1865367030 hasConcept C2776694085 @default.
• W1865367030 hasConcept C2776715498 @default.
• W1865367030 hasConcept C2776755627 @default.
• W1865367030 hasConcept C2777132456 @default.
• W1865367030 hasConcept C2777866208 @default.
• W1865367030 hasConcept C2778119113 @default.
• W1865367030 hasConcept C2779112685 @default.
• W1865367030 hasConcept C2779429289 @default.
• W1865367030 hasConcept C2780964509 @default.
• W1865367030 hasConcept C2909463153 @default.
• W1865367030 hasConcept C3019864225 @default.
• W1865367030 hasConcept C71924100 @default.
• W1865367030 hasConcept C90924648 @default.
• W1865367030 hasConceptScore W1865367030C126322002 @default.
• W1865367030 hasConceptScore W1865367030C141071460 @default.
• W1865367030 hasConceptScore W1865367030C2776232574 @default.
• W1865367030 hasConceptScore W1865367030C2776305933 @default.
• W1865367030 hasConceptScore W1865367030C2776694085 @default.
• W1865367030 hasConceptScore W1865367030C2776715498 @default.
• W1865367030 hasConceptScore W1865367030C2776755627 @default.
• W1865367030 hasConceptScore W1865367030C2777132456 @default.
• W1865367030 hasConceptScore W1865367030C2777866208 @default.
• W1865367030 hasConceptScore W1865367030C2778119113 @default.
• W1865367030 hasConceptScore W1865367030C2779112685 @default.
• W1865367030 hasConceptScore W1865367030C2779429289 @default.
• W1865367030 hasConceptScore W1865367030C2780964509 @default.
• W1865367030 hasConceptScore W1865367030C2909463153 @default.
• W1865367030 hasConceptScore W1865367030C3019864225 @default.
• W1865367030 hasConceptScore W1865367030C71924100 @default.
• W1865367030 hasConceptScore W1865367030C90924648 @default.
• W1865367030 hasIssue "4" @default.
• W1865367030 hasLocation W18653670301 @default.
• W1865367030 hasLocation W18653670302 @default.
• W1865367030 hasOpenAccess W1865367030 @default.
• W1865367030 hasPrimaryLocation W18653670301 @default.
• W1865367030 hasRelatedWork W1527933360 @default.
• W1865367030 hasRelatedWork W1722630428 @default.
• W1865367030 hasRelatedWork W1816475975 @default.
• W1865367030 hasRelatedWork W1865367030 @default.
• W1865367030 hasRelatedWork W1983722005 @default.
• W1865367030 hasRelatedWork W2053384420 @default.
• W1865367030 hasRelatedWork W2062569470 @default.
• W1865367030 hasRelatedWork W2068623214 @default.
• W1865367030 hasRelatedWork W2123159259 @default.
• W1865367030 hasRelatedWork W2171380046 @default.
• W1865367030 hasVolume "12" @default.
• W1865367030 isParatext "false" @default.
• W1865367030 isRetracted "false" @default.
• W1865367030 magId "1865367030" @default.
• W1865367030 workType "article" @default.